Please rate:

(TISI, KALU, SOMX) CRWENewswire Stocks to Watch


Description:

Somaxon Pharmaceuticals Incorporated - symbol SOMX - reported that it recently had a meeting with the FDA, who provided clinical and regulatory guidance relating to the over-the-counter development program for Silenor. Somaxon believes that Silenor’s characteristics, including its lack of addiction potential and its clinical efficacy and safety profile, make it an ideal candidate to be the first prescription insomnia product to be converted to an OTC product



Previous Media Next Media
Show more Show less

0 comments

No comments yet.



 
Visit Disclose.tv on Facebook